A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.
- Sponsor
- Photocure
- Study ID
- NCT00369018
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Cervical Dysplasia
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- methyl aminolevulinate (MAL) and hexaminolevulinate (HAL) — DRUGMAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
Study Details
The study will determine the best drug (MAL or HAL) dosage for photodynamic therapy of cervical precancerous lesions (dysplasia) in women that are referred for conisation (surgery).
Key Dates
- Start date
- Aug 31, 2006
- Status verified
- Nov 2010
- Primary completion
- Jul 31, 2009
- Completion
- Jul 31, 2009
Study Design
- Enrollment
- 96 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: MAL 3
- Active Comparator: MAL 12
- Active Comparator: HAL 10, 3
- Active Comparator: HAL 10, 12
- Active Comparator: HAL 40, 3
- Active Comparator: HAL 40, 12
Primary Outcome Measure
Lesion eradication [ Time Frame: 6 months ]
Related Studies
- Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)PHASE2 · Recruiting · Frantz Viral Therapeutics, LLC · Fort Myers, Florida
- The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical NeoplasiaEnrolling By Invitation · Guided Therapeutics · Birmingham, Alabama
- Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical CancerRecruiting · Mayo Clinic · Phoenix, Arizona
- Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic CancersRecruiting · Northwell Health · New York, New York